Varivax vaccine powder and solvent for suspension for injection 0.5ml vials Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

varivax vaccine powder and solvent for suspension for injection 0.5ml vials

merck sharp & dohme (uk) ltd - varicella-zoster virus live attenuated (oka/merck strain) - powder and solvent for suspension for injection

Crixivan Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

crixivan

merck sharp & dohme (new zealand) limited - indinavir sulfate 250mg equivalent to 200 mg indinavir;  ;   - capsule - 200 mg - active: indinavir sulfate 250mg equivalent to 200 mg indinavir     excipient: gelatin lactose magnesium stearate tekprint blue sb-6018 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts

Crixivan Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

crixivan

merck sharp & dohme (new zealand) limited - indinavir sulfate 416.3mg equivalent to 333 mg indinavir;  ;   - capsule - 333 mg - active: indinavir sulfate 416.3mg equivalent to 333 mg indinavir     excipient: gelatin lactose magnesium stearate

Crixivan Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

crixivan

merck sharp & dohme (new zealand) limited - indinavir sulfate 500mg equivalent to 400 mg indinavir;  ;   - capsule - 400 mg - active: indinavir sulfate 500mg equivalent to 400 mg indinavir     excipient: gelatin lactose magnesium stearate tekprint green sb-4020 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts

HBvaxPRO vaccine Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

hbvaxpro vaccine

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 10 µg/ml - suspension for injection - 10 mcg/ml - active: hepatitis b vaccine, rdna 10 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

HBvaxPRO vaccine Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

hbvaxpro vaccine

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 40 µg/ml - suspension for injection - 40 mcg/ml - active: hepatitis b vaccine, rdna 40 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

MMR II Vaccine Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

mmr ii vaccine

merck sharp & dohme (new zealand) limited - measles vaccine 1000 tcid50 (at end of expiry); mumps vaccine 12500 tcid50 (at end of expiry); rubella vaccine 1000 tcid50 (at end of expiry) - suspension for injection - active: measles vaccine 1000 tcid50 (at end of expiry) mumps vaccine 12500 tcid50 (at end of expiry) rubella vaccine 1000 tcid50 (at end of expiry) excipient: dibasic potassium phosphate dibasic sodium phosphate monohydrate eagle minimum essential medium gelatin medium 199 monobasic potassium phosphate monobasic sodium phosphate monohydrate monosodium glutamate neomycin phenolsulfonphthalein sodium bicarbonate sorbitol sucrose water for injection - m-m-r ii is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

Pneumovax 23 vaccine Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

pneumovax 23 vaccine

merck sharp & dohme (new zealand) limited - pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) - solution for injection - active: pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) excipient: phenol sodium chloride water for injection - pneumovax 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.

Primaxin Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

primaxin

merck sharp & dohme (new zealand) limited - cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage).; imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).;   - powder for infusion - 500mg/500mg - active: cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage). imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).   excipient: sodium bicarbonate

RotaTeq Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

rotateq

merck sharp & dohme (new zealand) limited - rotavirus reassortant strain g1 2.2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g2 2.8e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g3 2.2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g4 2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain p1 2.3e+006 [iu] (nlt, at expiry) - oral solution - 2 ml - active: rotavirus reassortant strain g1 2.2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g2 2.8e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g3 2.2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g4 2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain p1 2.3e+006 [iu] (nlt, at expiry) excipient: rotavirus diluent & lpkm-3 (from actives) to approx 0.3 ml. includes animal materials as below. monobasic sodium phosphate monohydrate polysorbate 80 purified water sodium citrate dihydrate sodium hydroxide sucrose - rotateq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, g4, and g-serotypes that contain p1a[8] (e.g., g9). rotateq may be administered as early as six weeks of age.